Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction

§ Tashkent Medical Academy

Send Message

To: Author

Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction

Article Fingerprint

ReserarchID

7JO5H

Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction Banner

Key Research Insights

Synthesized scholarly intelligence & interactive research assistant
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu
Reading Preferences
Font Size
Line Spacing
Background

I. INTRODUCTION

One of the consequences under the scrutiny of researchers is cognitive dysfunction in drug addiction. Abnormal brain function in people with addiction predisposes them to make decisions with disastrous consequences for their health and well-being, and the well-being of their families and communities [1]. Many authors point out that there is an extensive literature supporting the hypothesis that long-term drug exposure leads to certain cognitive impairments [2,3,4,5]. Among drug users, the prevalence of cognitive impairment ranges from 30 to 80% [6].

Areas of the brain and processes underlying addiction overlap significantly with areas involved in basic cognitive functions [7]. Anatomically, there is an important overlap between learning and memory neural substrates and addictions. Some of the areas that show overlap include the cerebral cortex, hippocampus, amygdala, and striatum, all of which are components of the mesolimbic dopaminergic system [8]. Cognitive dysfunctions are closely associated with a strong pathological craving for the drug, with its ideational and affective components being especially pronounced. The intensity of changes in the ideational component is confirmed, along with impairments in the cognitive sphere, impaired nosognosias in most patients in the post-withdrawal period [9]. A similar reflection was found in the article by Copersino M. L. and Wiers R. W. that cognitive impairment affects addictive behavior [10,11].

Yaltonsky V.M. "The combination of legal and illegal surfactants is manifested by high neurotoxicity, which is considered as one of the main causes of neurodegenerative disorders in chemical addictions and is accompanied by neurocognitive deficits" [12].

Many authors come to the conclusion that it is the cannabinoid group that is the main source of cognitive dysfunctions in combined abuse with tramadol [13,14], which depend on the age of onset, duration, amount, and frequency of abuse [15,16,17]. Tursunkhojaeva L.A., and Rustamova J.T. in a comparative assessment of memory functions in patients with opium-hashish poly-drug addiction and opium mono-addiction, we concluded that all amnestic processes are disturbed during poly-drug addiction [18].

Cognitive impairment is a predictor of poor treatment outcome [19,20]. Cognitive dysfunction also harms treatment processes such as motivation for treatment, willingness to change, readiness for treatment, and the rehabilitation period [21]. The preservation of cognitive functions in drug addicts can reduce the risk of relapse and improve the effectiveness of rehabilitation [22]. Predictors of low treatment success and a high likelihood of relapse are memory impairments, a low level of abstraction, low psychomotor speed and impaired visual-spatial synthesis, impaired inhibition processes, and working memory [23,24]. The patient's cognitive ability is a predictor of quality of treatment outcome, which can be a useful screening tool for alerting potential problems that may arise during treatment [25,26,27]. Repeated drug use in the face of negative consequences indicates dysfunction of the cognitive mechanisms underlying decision-making. The deficit in decision making is most likely due to both premorbid factors and effects caused by psychoactive substances, which in the long term is associated with a high risk of relapse [28.29].

Purpose: A neuropsychological study of cognitive functions in patients with combined dependence on hashish and tramadol.

II. MATERIALS AND RESEARCH METHODS

Following the goal of the study, 129 male patients were selected who underwent inpatient treatment for drug addiction in the Republican Narcological Center from 2015 to 2019. All patients are male. The patients were divided into 3 groups: group 1 (main group) - 41% of patients (n=53) with combined abuse of hashish and tramadol. For comparison, patients with opium and hashish monar addiction who were not complicated by dependence on other types of psychoactive substances were selected. 2- group (control group) -34% of patients (n=44) with dependence on opioids, abuse tramadol without a doctor's prescription to achieve euphoria, who did not use other opioids before taking tramadol. Group 3 (control group) - 24.8% of patients (n=32) with dependence on cannabinoids.

A neuropsychological study was carried out using two approaches: 1. a cognitive screening tool to distinguish between patients in the main and control groups. For the study of memory: a method of memorizing 10 words according to AR Luria, [30,31] words that are not related to each other, neutral in logic and emotional color. A set of words is presented 5 times so that the patient can fully remember them and can reproduce them in any sequence.

  1. A battery of tests to determine the relationship between disease and cognitive dysfunction - Montreal Cognitive Assessment Scale (MoCA test) [32,33]. The MoCA test is sensitive to subtle cognitive impairments in a variety of populations and has a wide range of applications, including dependence on psychoactive substances [34], in contrast to MMSE (Mini-mental state examination (MMSE) MF Folstein, PR Folstein (1975), the MOSA test is more sensitive to early detection of cognitive decline. [35] The MOCA test helps to assess: executive functions, optical-spatial activity, memory, attention, speech, conceptual thinking, counting, and orientation. The sensitivity is 90%, the specificity of the method is 87%. The maximum score is 30; the cut-off point is 25/26 points [36,37]. Time for the test is approximately 10 minutes. When concluding, they were not based only on rating scales, we took into account the anamnestic information collected from the patient, as well as, if possible and the consent of the patient and his close relatives, mental status, and our observations.

The data revealed during the study were subjected to statistical processing on a Pentium-IV personal computer using the Microsoft Office Excel-2016 software package, using the built-in statistical processing functions. The level of reliability P < 0.05 was taken as statistically significant changes. All patients had informed consent for examination.

III. RESULTS AND DISCUSSION

The age of the surveyed ranged from 20 to 45 years. The average age is 30.5±6.16 years. The average age of patients at the time of examination in group 1 was 31.1±7.0 years (median 31.5; minimum age - 20 years, maximum age 45 years), in group 2 - 30.06±6.7 years (median 29.5; minimum age 20 years, maximum age 45 years), in group 3 - 31.6±7.1 (median 32.5; minimum age 22 years, maximum age 44 years).

The result of the study of the level of education, presented in Figure 1, did not reveal statistically significant intergroup differences (P 1-2, P 1-3 > 0.05).

Figure 1: Distribution of respondents by education level in the study groups. Note: differences relative to data from groups II and III are insignificant (P  loading= 0.05)" data-thumbhash="NwgKDIKlecppiIefd5VltmBmCg==" style="display: block; width: 100%; height: 100%; object-fit: contain;" decoding=async height=529 loading=lazy src=https://doc.globaljournals.org/lwco65_60310/ocr/images/derivatives/8e/8e55533f2f8de6b5a063096b6f2f1caa1ffb1b5e1d98dc1bc4d923f49f6c3b35.webp width=946>
Figure 1: Distribution of respondents by education level in the study groups. Note: differences relative to data from groups II and III are insignificant (P > 0.05)

Among the patients of the studied groups, cognitive impairments of varying severity were revealed.

The results of the study of memory by the method of memorizing 10 words showed that after the first series, which indicates the volume of auditory short-term memory, a large proportion of patients with combined addiction remembered only 2-4 words: 67.9% of patients in group 1, 11.3% patients in group 2 (P1-2 <0.001) and 53.1% of patients in group 3 (P 1-3 > 0.05), in contrast, were able to reproduce 5-7 words in patients with tramadol dependence (32% of patients 1- group, 88.6% of patients in group 2 (P 1-2 <0.001) and 46.8% of patients in group 3 (P 1-3 > 0.05).

When examining subjects without memory impairments, by the third repetition they reproduce, correctly, up to 9 or 10 words. Substance-dependent patients gave the following results (Table 1).

Table 1: Distribution of patients according to the results of the number of words after the third attempts
Word count1st group(n=53)2nd group(n=44)3rd group(n=32)P1−2P1−3
abc.%abc.%abc.%
2-4611,30039,3<0,05>0,05
5-73158,4613,61340,6<0,001<0,01
8-101630,13886,31650<0,001>0,05
Total531004410032100

The indicators of the volume of auditory long-term memory, taken after one hour, determined that the vast majority of patients with tramadol dependence could reproduce 8-10 words (18.8% of patients in group 1, 81.8% of patients in group 2 (P1-2 <0.001) and

Figure 2: Shows the curves of memorization in the studied groups and in the norm.
Figure 2: Shows the curves of memorization in the studied groups and in the norm.

Normally, the learning curve is steadily increasing. The curve of patients in groups 1 and 3 reflects violations of all mnemonic processes - fixation, retention and reproduction. Their curve with a sharp downward slope indicates a weakening of active attention. Although the curves of patients in groups 1 and 3 are the same, the number of words in the initial and subsequent reproductions is lower with combined dependence on hashish and tramadol than with mono use of hashish. And also patients in group 1 often reproduced words in random order with the aim of not specifically highlighting previously unmentioned words. Having made a mistake, they continued to repeat it in the next tests.

Screening of cognitive function with the MOSA test also revealed intergroup differences. The average score on the MOSA test was higher among patients in group 2 - 24.5±1.15 (P1-2 <0.01), for patients in group 1 it was 21.4±2.42 and in patients in group 3 - 22.81±1, 09 (P 1-3 > 0.05). Table 2 shows the indicators of each domain of the MOCA scale in the subjects.

Table 2: Distribution of patients according to the results of the IOCA test
Indicators1 Group(n=53)2Group(n=44)3 Group(n=32)P1−2P1−3
abc.%abc.abc.%abc.
Draw a broken line:
wrong1834,012,3618,8<0,001>0,05
right3566,04397,72681,3<0,001>0,05
Optical-spatial activity (cube):
wrong2547,21431,81237,5>0,05>0,05
right2852,83068,22062,5>0,05>0,05
Optical-spatial activity (hours):
Контур:
wrong35,70026,3>0,05>0,05
right5094,3441003093,8>0,05>0,05
Numbers:
wrong1528,349,1618,8<0,001>0,05
right3871,74090,92681,3<0,01>0,05
Arrows
wrong2037,7920,51031,3>0,05>0,05
right3362,33579,52268,8>0,05>0,05
Naming:
Llion
wrong000000
right531004410032100
Rhinoceros
wrong1630,21636,41650,0>0,05>0,05
right3769,82863,61650,0>0,05>0,05
Camel
wrong59,449,139,4>0,05>0,05
right4890,64090,92990,6>0,05>0,05
Attention:
Direct account
wrong2139,61636,41237,5>0,05>0,05
right3260,42863,62062,5>0,05>0,05
Reverse count
wrong713,2818,2618,7>0,05>0,05
right4686,83681,82681,2>0,05>0,05
Reaction (clap on the letter A)
wrong1120,8818,2721,9>0,05>0,05
right4279,23681,82578,2>0,05>0,05
Serial account
1 score35,70000>0,05>0,05
2 score3158,52045,51856,2>0,05>0,05
3 score1935,82454,51443,7>0,05>0,05
Repeating a sentence I
wrong4281,13170,52371,8>0,05>0,05
right1118,91329,5928,1>0,05>0,05
Repeating a sentence II
wrong35662556,82062,5>0,05>0,05
right1834,01943,21237,5>0,05>0,05
Fluency of speech:
wrong2344,41431,81134,4>0,05>0,05
right3056,63068,22165,6>0,05>0,05
Abstract thinking:
1 score2445,31943,21443,8>0,05>0,05
2 score2954,72556,81856,3>0,05>0,05
Delayed playback:
1 score59,40000<0,05>0,05
2 score1528,30039,4<0,001<0,05
3 score2547,2715,91134,4<0,001>0,05
4 score815,12045,51856,3<0,001<0,001
5 score001738,600<0,001
Orientation:
4 score23,80000>0.05>0.05
5 score2852,82045,51546,9>0.05>0.05
6 score2343,42454,51753,1>0.05>0.05

Among all patients with addiction to psychoactive substances, more violations were revealed in such parameters as executive skills - drawing a broken line: correct performance was 66% in group 1, 97.7% in group 2 (P1-2 <0.001), 3-group 81.3% (P1-3 >0.05). Any mistake, if corrected by the patient on his own, was counted. When assessing optical-spatial activity (cube): intergroup differences were not revealed (P1-2; P1-3 >0.05); Optical-spatial activity (hours): when drawing the correct contour and the arrangement of arrows, intergroup differences were not revealed (P1-2; P1-3 >0.05); the correct arrangement of numbers - patients in group 1 - 71.7%, group 2 - 90, 9% (P1-2 <0.01), 3 groups 81.3% (P1-3 >0.05). Delayed reproduction (score is assigned 1 point for each named word without any prompts): 1 point was received only by patients of group 1, 9.4% (P1-2; P1-3 <0.05); 2 points - patients in group 1 - 28.3%, group 2 did not receive (P1-2 <0.001), group 3 - 9.4% (P1-3 >0.05); 3 points - patients of group 1 - 47.2%, group 2 - 15.9% (P1-2 <0.001), group 3 - 34.4% (P1-3 >0.05) 4 points - patients 1 - group 15.1%, group 2 45.5% (P1-2 <0.001), group 3 56.3% (P1-3 <0.001); 5 points - only patients in group 2 38.6% (P1-2 <0.001). In the remaining domains, such as naming, attention, repetition of sentences in two approaches, fluency, abstract thinking and orientation, no statistically intergroup differences were found (P1-2; P1-3> 0.05). But draws attention, all patients of the study groups, 100% correctly named the animal "lion", while the naming of the animal "rhino" had difficulties in patients of group 3 (group 1 - 69.8% answered correctly, group 2 63.6%, group 3 - 50.0% (P1-2; P1-3> 0.05) All patients in the study of attention had difficulties in direct counting, the proportion of correct answers was low (group 1 - 60.4%; Group 2 - 63.6%; Group 3 -62.5% (P1-2; P1-3> 0.05) compared to the reverse count (Group 1 -86.8%; Group 2 -81.8%; Group 3-81.2% (P1-2; P1-3> 0.05)).

Conclusion: Screening of cognitive functions in patients with the combined use of hashish and tramadol showed that there is a negative synergistic effect on cognitive function. The cannabinoid group is the main cognitive dysfunction when combined with tramadol - with combined use and mono use of hashish, violations of all mnemonic processes occur: fixation, retention, and reproduction, but with deeper disorders in poly addiction.

Screening of the cognitive function of patients with poly addiction is one of the main prognostic signs and gives an idea to the clinician for a further algorithm of actions, directions for improving the specialized treatment of addiction and preventing the relapse of the disease.

References

34 Cites in Article
  1. 1. (2020). UNODC/WHO International Standards for the Treatment of Drug Use Disorders. UNODC/WHO International Standards for the Treatment of Drug Use Disorders
  2. 2. H Curran,Tom Freeman,Claire Mokrysz,David Lewis,Celia Morgan,Loren Parsons (2016). Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience, 17(5), 293-306.
  3. 3. M Field,W Cox (2008). Attentional bias in addictive behaviors: A review of its development, causes, and consequences. Drug and Alcohol Dependence, 97(1-2), 1-20.
  4. 4. C Perry,A Lawrence (2017). Addiction, cognitive decline and therapy: seeking ways to escape a vicious cycle. Genes, brain, and behavior, 16(1), 205-218.
  5. 5. Nora Volkow,James Swanson,A Evins,Lynn Delisi,Madeline Meier,Raul Gonzalez,Michael Bloomfield,H Curran,Ruben Baler (2016). Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry, 73(3), 292.
  6. 6. Egon Hagen,Aleksander Erga,Katrin Hagen,Sverre Nesvåg,James Mckay,Astri Lundervold,Espen Walderhaug (2016). Assessment of Executive Function in Patients With Substance Use Disorder: A Comparison of Inventory- and Performance-Based Assessment. Journal of Substance Abuse Treatment, 66, 1-8.
  7. 7. T Gould (2010). Addiction and cognition. Addiction science & clinical practice, 5(2), 4-14.
  8. 8. Claudia Juárez,Tania Molina-Jiménez,Jean-Pascal & Morin,Roldán-Roldán,& Gabriel,Rossana Zepeda (2018). Influence of Drugs on Cognitive Functions. Influence of Drugs on Cognitive Functions
  9. 9. T Agibalova,K Poplevchenkov (2012). Clinical symptoms and personality traits in patients using psychostimulant drugs and other psychoactive substances. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 118(1), 10.
  10. 10. Marc Copersino (2017). Cognitive mechanisms and therapeutic targets of addiction. Current Opinion in Behavioral Sciences, 13, 91-98.
  11. 11. R Wiers,A Stacy (2006). Implicit Cognition and Addiction. Current Directions in Psychological Science, 15(6), 292-296.
  12. 12. V Yaltonsky,N Sirota,A Yaltonskaya (2017). The combined use of drugs and other psychoactive substances by adolescents as an urgent problem of narcology. // Issues of narcology. The combined use of drugs and other psychoactive substances by adolescents as an urgent problem of narcology. // Issues of narcology, 83, 88.
  13. 13. Medhat Bassiony,Usama Youssef,Mervat Hassan,Ghada Salah El-Deen,Hayam El-Gohari,Mohamed Abdelghani,Ahmed Abdalla,Dalia Ibrahim (2017). Cognitive Impairment and Tramadol Dependence. Journal of Clinical Psychopharmacology, 37(1), 61-66.
  14. 14. Y Miao,J Tian,J Shi,M Mao (2012). Effects of Chinese medicine for tonifying the kidney and resolving phlegm and blood stasis in treating patients with amnestic mild cognitive impairment: A randomized, double-blind and parallel-controlled trial. Journal of Chinese Integrative Medicine, 10(4), 390-397.
  15. 15. Amir Levine,Kelly Clemenza,Moira Rynn,Jeffrey Lieberman (2017). Evidence for the Risks and Consequences of Adolescent Cannabis Exposure. Journal of the American Academy of Child & Adolescent Psychiatry, 56(3), 214-225.
  16. 16. Dan Lubman,Ali Cheetham,Murat Yücel (2015). Cannabis and adolescent brain development. Pharmacology & Therapeutics, 148, 1-16.
  17. 17. A Shrivastava,M Johnston,M Tsuang (2011). Cannabis use and cognitive dysfunction. Indian journal of psychiatry, 53(3), 187-191.
  18. 18. L Tursunkhojaeva,T Rustamova Zh (2007). Comparative assessment of memory functions in patients with opium-hashish poly drug addiction and opium mono-drug addiction // Neurology. Comparative assessment of memory functions in patients with opium-hashish poly drug addiction and opium mono-drug addiction // Neurology, 334.
  19. 19. Marc Copersino,David Schretlen,Garrett Fitzmaurice,Scott Lukas,Judith Faberman,Jody Sokoloff,Roger Weiss (2012). Effects of Cognitive Impairment on Substance Abuse Treatment Attendance: Predictive Validation of a Brief Cognitive Screening Measure. The American Journal of Drug and Alcohol Abuse, 38(3), 246-250.
  20. 20. Mehmet Sofuoglu (2010). Cognitive enhancement as a pharmacotherapy target for stimulant addiction. Addiction, 105(1), 38-48.
  21. 21. Marc Copersino,William Fals-Stewart,Garrett Fitzmaurice,David Schretlen,Jody Sokoloff,Roger Weiss (2009). Rapid cognitive screening of patients with substance use disorders. Experimental and Clinical Psychopharmacology, 17(5), 337-344.
  22. 22. Linwei Wang,Jeong Min,Emanuel Krebs,Elizabeth Evans,David Huang,Lei Liu,Yih-Ing Hser,Bohdan Nosyk (2017). Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. International Journal of Drug Policy, 49, 32-40.
  23. 23. A Polunina,D Davydov,E Brun (2004). Neuropsychological studies of cognitive impairments in alcoholism and drug addiction // Psychological journal. Neuropsychological studies of cognitive impairments in alcoholism and drug addiction // Psychological journal, 25, 70-76.
  24. 24. Sultanov Sh,Kh,N Khodzhaeva,A Kharyakova (2019). Correction of cognitive impairments in heroin addiction with the nootropic drug alcheba (memantine) // Anthology of Russian psychotherapy and psychology. Correction of cognitive impairments in heroin addiction with the nootropic drug alcheba (memantine) // Anthology of Russian psychotherapy and psychology, 168.
  25. 25. J Allan,S Collings,A Munro (2019). The process of change for people with cognitive impairment in a residential rehabilitation program for substance problems: a phenomenographical analysis. Substance abuse treatment, prevention, and policy, 14(1), 13.
  26. 26. K Carroll,B Kiluk,C Nich,T Babuscio,J Brewer,M Potenza,S Ball,S Martino,B Rounsaville,C Lejuez (2011). Cognitive function and treatment response in a randomized clinical trial of computer-based training in cognitivebehavioral therapy. Substance use & misuse, 46(1), 23-34.
  27. 27. Sara Domínguez-Salas,Carmen Díaz-Batanero,Oscar Lozano-Rojas,Antonio Verdejo-García (2016). Impact of general cognition and executive function deficits on addiction treatment outcomes: Systematic review and discussion of neurocognitive pathways. Neuroscience & Biobehavioral Reviews, 71, 772-801.
  28. 28. Antonio Yam,Trevor Chong,Julie Stout,Yucel,Edythe Murat & London (2017). Stages of dysfunctional decision-making in addiction. Pharmacology Biochemistry and Behavior, 164
  29. 29. K Willock,Н Сапронов (2010). Screening Drug and Alcohol participants for mild cognitive impairment: why, how and does it matter? 30. Screening Drug and Alcohol participants for mild cognitive impairment: why, how and does it matter? 30, 10, 229.
  30. 30. Ziad Nasreddine,Natalie Phillips,Valérie Bédirian,Simon Charbonneau,Victor Whitehead,Isabelle Collin,Jeffrey Cummings,Howard Chertkow (2005). The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. Journal of the American Geriatrics Society, 53(4), 695-699.
  31. 31. Parunyou Julayanont,Natalie Phillips,Howard Chertkow,Ziad Nasreddine (2013). Montreal Cognitive Assessment (MoCA): Concept and Clinical Review. Cognitive Screening Instruments, 111-151.
  32. 32. А Ivkin,E Grigoriev,D Shukevich (2018). DIAGNOSTICS OF COGNITIVE DYSFUNCTION IN PATIENTS IN THE INTENSIVE CARE WARDS. Messenger OF ANESTHESIOLOGY AND RESUSCITATION, 15(3), 47-55.
  33. 33. John Hobson (2015). The Montreal Cognitive Assessment (MoCA). Occupational Medicine, 65(9), 764-765.
  34. 34. Alessandra Thomann,Nicolai Goettel,Raphael Monsch,Manfred Berres,Thomas Jahn,Luzius Steiner,Andreas Monsch (2018). The Montreal Cognitive Assessment: Normative Data from a German-Speaking Cohort and Comparison with International Normative Samples. Journal of Alzheimer's Disease, 64(2), 643-655.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Inara Khayretdinova, Zarifjon Ashurov, Nargiza Yadgarova. 2020. "Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction". Global Journal of Medical Research - A: Neurology & Nervous System GJMR-A Volume 20 (GJMR Volume 20 Issue A3).

More Citation Formats

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-A Classification NLMC Code: WS 462
Version of record

v1.2

Issue date
October 24, 2020

Language
English
Order Article Reprint
Experience in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 1K
Total Downloads: 89
All Trends

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction

Inara Khayretdinova
Inara Khayretdinova <p>Tashkent Medical Academy</p>
Zarifjon Ashurov
Zarifjon Ashurov
Nargiza Yadgarova
Nargiza Yadgarova